Cargando…
Targeting macrophages: a novel treatment strategy in solid tumors
In the tumor microenvironment (TME), tumor-associated macrophages (TAMs) are the most abundant immune cells, which act as a key regulator in tumorigenesis and progression. Increasing evidence have demonstrated that the TME alters the nature of macrophages to maintain dynamic tissue homeostasis, allo...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743606/ https://www.ncbi.nlm.nih.gov/pubmed/36510315 http://dx.doi.org/10.1186/s12967-022-03813-w |
_version_ | 1784848758488432640 |
---|---|
author | Liu, Mengmeng Liu, Lina Song, Yongping Li, Wei Xu, Linping |
author_facet | Liu, Mengmeng Liu, Lina Song, Yongping Li, Wei Xu, Linping |
author_sort | Liu, Mengmeng |
collection | PubMed |
description | In the tumor microenvironment (TME), tumor-associated macrophages (TAMs) are the most abundant immune cells, which act as a key regulator in tumorigenesis and progression. Increasing evidence have demonstrated that the TME alters the nature of macrophages to maintain dynamic tissue homeostasis, allowing TAMs to acquire the ability to stimulate angiogenesis, promote tumor metastasis and recurrence, and suppress anti-tumor immune responses. Furthermore, tumors with high TAM infiltration have poor prognoses and are resistant to treatment. In the field of solid tumor, the exploration of tumor-promoting mechanisms of TAMs has attracted much attention and targeting TAMs has emerged as a promising immunotherapeutic strategy. Currently, the most common therapeutic options for targeting TAMs are as follows: the deletion of TAMs, the inhibition of TAMs recruitment, the release of phagocytosis by TAMs, and the reprogramming of macrophages to remodel their anti-tumor capacity. Promisingly, the study of chimeric antigen receptor macrophages (CAR-Ms) may provide even greater benefit for patients with solid tumors. In this review, we discuss how TAMs promote the progression of solid tumors as well as summarize emerging immunotherapeutic strategies that targeting macrophages. |
format | Online Article Text |
id | pubmed-9743606 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97436062022-12-13 Targeting macrophages: a novel treatment strategy in solid tumors Liu, Mengmeng Liu, Lina Song, Yongping Li, Wei Xu, Linping J Transl Med Review In the tumor microenvironment (TME), tumor-associated macrophages (TAMs) are the most abundant immune cells, which act as a key regulator in tumorigenesis and progression. Increasing evidence have demonstrated that the TME alters the nature of macrophages to maintain dynamic tissue homeostasis, allowing TAMs to acquire the ability to stimulate angiogenesis, promote tumor metastasis and recurrence, and suppress anti-tumor immune responses. Furthermore, tumors with high TAM infiltration have poor prognoses and are resistant to treatment. In the field of solid tumor, the exploration of tumor-promoting mechanisms of TAMs has attracted much attention and targeting TAMs has emerged as a promising immunotherapeutic strategy. Currently, the most common therapeutic options for targeting TAMs are as follows: the deletion of TAMs, the inhibition of TAMs recruitment, the release of phagocytosis by TAMs, and the reprogramming of macrophages to remodel their anti-tumor capacity. Promisingly, the study of chimeric antigen receptor macrophages (CAR-Ms) may provide even greater benefit for patients with solid tumors. In this review, we discuss how TAMs promote the progression of solid tumors as well as summarize emerging immunotherapeutic strategies that targeting macrophages. BioMed Central 2022-12-12 /pmc/articles/PMC9743606/ /pubmed/36510315 http://dx.doi.org/10.1186/s12967-022-03813-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Liu, Mengmeng Liu, Lina Song, Yongping Li, Wei Xu, Linping Targeting macrophages: a novel treatment strategy in solid tumors |
title | Targeting macrophages: a novel treatment strategy in solid tumors |
title_full | Targeting macrophages: a novel treatment strategy in solid tumors |
title_fullStr | Targeting macrophages: a novel treatment strategy in solid tumors |
title_full_unstemmed | Targeting macrophages: a novel treatment strategy in solid tumors |
title_short | Targeting macrophages: a novel treatment strategy in solid tumors |
title_sort | targeting macrophages: a novel treatment strategy in solid tumors |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743606/ https://www.ncbi.nlm.nih.gov/pubmed/36510315 http://dx.doi.org/10.1186/s12967-022-03813-w |
work_keys_str_mv | AT liumengmeng targetingmacrophagesanoveltreatmentstrategyinsolidtumors AT liulina targetingmacrophagesanoveltreatmentstrategyinsolidtumors AT songyongping targetingmacrophagesanoveltreatmentstrategyinsolidtumors AT liwei targetingmacrophagesanoveltreatmentstrategyinsolidtumors AT xulinping targetingmacrophagesanoveltreatmentstrategyinsolidtumors |